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cAMPcAMP signaling is an evolutionarily conserved intracellular communication system controlling numerous cellular
functions. Until recently, transmembrane adenylyl cyclase (tmAC) was considered the major source for cAMP in
the cell, and the role of cAMP signaling was therefore attributed exclusively to the activity of this family of
enzymes. However, increasing evidence demonstrates the role of an alternative, intracellular source of cAMPpro-
duced by type 10 soluble adenylyl cyclase (sAC). In contrast to tmAC, sAC produces cAMP in various intracellular
microdomains close to speciﬁc cAMP targets, e.g., in nucleus and mitochondria. Ongoing research demonstrates
involvement of sAC in diverse physiological and pathological processes. The present review is focused on the role
of cAMP signaling, particularly that of sAC, in cell death and growth. Although the contributions of sAC to the reg-
ulation of these cellular functions have only recently been discovered, current data suggest that sAC plays key
roles in mitochondrial bioenergetics and the mitochondrial apoptosis pathway, as well as cell proliferation and
development. Furthermore, recent reports suggest the importance of sAC in several pathologies associated
with apoptosis aswell as in oncogenesis. This article is part of a Special Issue entitled: The role of soluble adenylyl
cyclase in health and disease.e of soluble adenylyl cyclase in
ascular Research, Charité-
Berlin, Germany. Tel.: +49 234© 2014 Elsevier B.V. All rights reserved.1. Introduction
The discovery of the second messenger cAMP by Earl Wilbur
Sutherland in 1958 [1] opened new perspectives in understanding
the underlyingmechanisms of the signaling processes that occurwithin
and between cells. Intense researchduring the ensuing decades demon-
strated that cAMP signaling is evolutionarily conserved and can be
found in all species, from microorganisms to mammals. In animals,
cAMPplays a fundamental role in numerous physiological processes, in-
cluding development, organ and tissue homeostasis, aging and death.
Furthermore, extensive and ongoing research established that cAMP
signaling is involved in several pathogenesis, e.g., cancer, neurodegen-
eration, heart failure, and diabetes [2]. Although cAMP contributes
to the regulation of hundreds cellular functions, two key classes of
proteins control its cellular concentration. These classes are adenylyl
cyclases, which synthetize cAMP, and cyclic nucleotide phosphodiester-
ases (PDEs), which degrade cAMP. To properly regulate diverse cellular
functions, precision and target speciﬁcity of cAMP signaling is very
important. Such precise signaling is predominantly deﬁned by intracel-
lular compartmentalization of three main downstream effectors forcAMP: protein kinase A (PKA), exchange protein activated by cAMP
(EPAC) and cyclic nucleotide-gated ion channels. Additionally, selectivity
and speciﬁcity of cAMP signaling rely on the compartmentalization of
adenylyl cyclases, i.e., (i) transmembrane adenylyl cyclase (tmAC)within
the plasmalemma, and (ii) soluble adenylyl cyclase (sAC) in the cytosol
and within distinct organelles. In the present review, we have focused
on sAC-dependent cAMP-signaling. Research in this ﬁeld has revealed a
contribution of sAC in numerous physiological and pathological process-
es. Here we described recent data about the contribution of sAC in cell
death and growth.
2. cAMP signaling
2.1. Adenylyl cyclase
The conversion of ATP to cAMP is catalyzed by adenylyl cyclases,
which represent a large family of enzymes consisting of six classes. In
mammalian cells, cAMP is generated by class III adenylyl cyclases, a
group consisting of tenmembers. Ninemembers of this class of cyclases
belong to the tmAC subfamily. They share a common structural organi-
zation: 12 transmembrane helices and 2 cytoplasmic domains that form
a (pseudo) heterodimer [3]. The tmAC contains two cytoplasmic
domains forming the catalytic core of the enzyme with the active site
at their interface [4,5]. The mechanisms controlling the activation and
inhibition of tmAC by Gs and Gi proteins, respectively, are shared by
all 9 types of tmACs, thereby allowing tmAC activity to be controlled
by hormones or neurotransmitters. In contrast, tmACs differ in their
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some types of tmACs may be activated through phosphorylation by
Ca2+/calmodulin-dependent protein kinase (types 1 and 8), by PKC
(types 2,3,5,7), or by binding of calmodulin (types 1 and 8) [6]. Further-
more, tmACs type 4 and 5 can be inhibited by PKA-dependent phos-
phorylation or by Ca2+ binding [6]. This type-dependent regulation of
tmAC activity, combined with differences in their tissue distribution/
expression, facilitates the selectivity and speciﬁcity of cAMP signaling
in different cell types and tissues.
According to the traditional model of cAMP-signaling, cAMP gener-
ated by tmAC freely diffuses throughout the cytosol and leads to
the activation of three known downstream targets: PKA, EPAC and
cyclic nucleotide-gated ion channels. However, the diffusion of cAMP
throughout the cytosol makes it difﬁcult to selectively activate dis-
tally localized targets without also activating more proximal targets,
i.e., localized at the plasmalemma. Therefore, such cAMP diffusion
would likely diminish speciﬁcity, selectivity and signal strength, and
this model of cAMP signaling has changed over the years. In fact,
cAMP diffusion is restricted within deﬁned compartments due to PDE
activity [7]. And it is now known that tmAC can continue to signal with-
in the cell during internalization/endocytosis along with G-protein-
coupled receptors, thereby deﬁning endocytic cAMP microdomains [8,
9]. Apart from tmAC, a second intracellular source of cAMP, type
10 sAC, was identiﬁed in mammalian cells [10]. Unlike tmAC, sAC
possesses no transmembrane domains and is localized throughout the
cell, e.g., in the cytosol, nucleus,mitochondria, and centriole [11]. There-
fore, in contrast to tmAC, sAC produces cAMP in different intracellular
microdomains close to speciﬁc cAMP targets. The activity of sAC, along
with the actions of PDEs limiting cAMP diffusion [7] and preventing
non-speciﬁc effector activation, enables both speciﬁcity and selectivity
towards intracellular targets. In addition, sAC can be activated by
divalent cations (e.g., Ca2+, Mg2+, Mn2+) and is therefore involved in
Ca2+ signaling. sAC also represents a unique intracellular bicarbonate
sensor with enzymatic activity. Finally, a recent study by Zippin et al.
[12] demonstrated that sAC-generated cAMP in β-cells reﬂects
alterations in intracellular ATP, suggesting that sAC also serves as an
intracellular ATP sensor.
sAC is expressed in all tissues and cells examined thus far. Although
encoded by a single gene, multiple isoforms are generated by alterna-
tive splicing. The longest mammalian isoform represents full-length
sAC (187 kDa) and is found predominantly in sperm [13]. Several
shorter-length sAC proteins have also been identiﬁed, with predomi-
nant expression of a ~50 kDa protein that possesses about tenfold
higher activity compared with full-length sAC. This isoform contains
two catalytic domains. Additionally, several splicing variants of sAC,
which have an altered or missing ﬁrst catalytic domain (C1), have
been identiﬁed inmouse and human cells [14–16]. However, it remains
unclear whether these sAC variants with altered C1 domain have
nucleotidyl cyclase activity [16,17]. Altogether, the presence of two
sources of cAMP, namely, tmAC and sAC, offers the possibility for the
selective regulation of diverse cellular functions.
2.2. Phosphodiesterases
cAMP synthesized by tmAC leads to the rapid activation of numerous
effector proteins localized within the plasmalemma. Although cAMP is
an easily diffusible molecule, its rapid diffusion throughout the cytosol
would lead to the uncontrolled activation of diverse intracellular
targets, thereby limiting the speciﬁcity of cAMP signaling. Cells have
therefore developed mechanisms to limit the diffusion of cAMP and
produce a membrane-to-cytosol cAMP concentration gradient [7,18].
PDEs play a key role in maintaining the gradient by hydrolyzing cAMP
to 5-AMP and providing diffusional barriers [19,20]. In turn, PDEs co-
localized with sAC in the cytosol or within diverse intracellular
compartments may also prevent the uncontrolled diffusion of cAMP
synthesized by sAC. Recent data also demonstrated that PDEs aretargeted to discrete signaling complexes together with other cAMP
effectors (PKA, EPAC) and their target proteins [21]. These complexes
therefore permit the sculpting of local cAMP gradients and provide for
the efﬁcient activation of spatially localized targets. Furthermore, the
co-localization of PDEs and PKA within one microdomain plays an im-
portant role in terminating the PKA-mediated phosphorylation of target
proteins [19].
The existence of more than 100 PDE isoforms resulting from the
differential expression and splicing of 11 PDE gene families [22] likely
contributes to the specialized function and localization of PDEs. Localiza-
tion of PDEs at themembrane or in the cytosol depends on the hydropho-
bicity of the NH2-terminal domains. For example, the hydrophobicity of
the NH2-termini of PDE2A3, PDE2A3 and PDE3 provides for their mem-
brane association [23]. Aside fromPDE isoforms that selectively hydrolyze
cAMP (PDE4, 7 and 8), some PDEs are cGMP-selective (PDE5, 6, and 9),
whereas others (PDE1, 2, 3, 10, and 11) can hydrolyze both cAMP and
cGMP. Interestingly, a recent study by Kim et al. [24] suggests a role for
PDE4D as a molecular transducer of cAMP signaling independent of its
classical enzymatic function. In summary, PDEs enable the speciﬁcity
and selectivity of cAMP signaling by limiting the cytosolic cAMP diffusion
and restricting the cAMP pool within distinct cellular compartments.
2.3. cAMP effectors
Three groups of direct cAMP effectormolecules have been described,
which play a key role in the complexity and speciﬁcity of cAMP signal-
ing. Of these, PKA is the best characterized. This serine/threonine kinase
is a tetrameric enzyme composed of two regulatory (R) and two catalyt-
ic (C) subunits. In unstimulated cells, with low cAMP concentration, the
C subunits are inhibited via binding by the R subunits. Upon the binding
of cAMP to each R subunit, the C subunits dissociate and become free to
phosphorylate their substrates [25]. A structurally diverse group of
proteins called A-kinase anchoring proteins (AKAP) bind R subunits
and promote the localization of the PKA holoenzyme within distinct
intracellular microdomains, e.g., the mitochondria, nucleus or plasma-
lemma. Furthermore, AKAP also act as scaffolds for PKA substrates,
PDEs and protein phosphatases, facilitating the regulation of cAMP
signaling [19,26–30].
The other important effectors of cAMP are EPAC, a guanine-
nucleotide exchange factor, and two groups of cyclic nucleotide regulat-
ed channels, namely, cyclic nucleotide-gated channels [31–34] and
hyperpolarization-activated cyclic nucleotide-gated channels [35–38].
Because these channels are mainly expressed in the plasmalemma,
they are primarily under the control of tmAC activity. Although they
play a role in diverse cellular functions, little is known about their con-
tribution to the regulation of cell death and growth. In contrast, EPAC
has been shown to localize to the cytosol, nucleus or mitochondria
[39,40], and it signiﬁcantly contributes to the control of apoptosis and
proliferation. The concentration of cAMP required to activate puriﬁed
EPAC in vitro was initially determined to be approximately 10-fold
higher than the concentration which activates PKA [41]. However,
recent data indicate that EPAC and PKA have similar afﬁnities for
cAMP in cells, suggesting that both effectors respond to physiologically
relevant cAMP concentrations [42]. There are two EPAC isoforms, EPAC1
and EPAC2, which are expressed in various tissues [43]. When bound
to cAMP, EPAC activates the small GTPases Rap1 and Rap2, which are
upstream of several signaling cascades. Similar to PKA, EPAC isoforms
seem to be spatially and temporally regulated and exert their biological
functions through interactions with various scaffold proteins such as
AKAPs, ezrin–radixin–moesin proteins, nuclear distribution element-
like protein, and the small G protein Ran and Ran binding protein 2 [40].
3. Role of cAMP signaling in cell death
In adult organisms, tissue homeostasis depends on the balance
between cell proliferation and the removal of cells by programmed
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to various diseases, e.g., cancer. Two main forms of programmed
cell death have been described: apoptosis and autophagy [44]. Although
programmed necrosis has also been proposed [45,46], it remains a
subject of debate. Apoptosis is characterized by a series of morpho-
logical alterations including cell shrinkage, plasmalemmal blebbing,
nuclear condensation and fragmentation, and the formation of apo-
ptotic bodies [47,48]. Autophagy is a self-degradative process trig-
gered by nutrient starvation or infection that is characterized by
the lysosomal degradation of cellular proteins and organelles within
the cell via the autophagosome in order to maintain cellular energy
levels [44,49,50].
Apoptosis is the best characterized form of the programmed cell
death. It seems to play a fundamental role in cellular/organismal
homeostasis and pathology. Apoptosis can be induced through at least
two main types of pathways: the extrinsic pathway (death receptor)
and the intrinsic pathways (mitochondria or endoplasmic reticulum).
Apoptosis is regulated by several intracellular signaling systems,
e.g., MAPK, Akt, TNFalpha and cAMP signaling [51–55]. Deﬁnitive
evidence for the essential role of cAMP in apoptosis was obtained
through studies using a variety of the cAMP-elevating agents, such as
membrane-permeable cAMP analogs, tmAC activators (forskolin or
cholera toxin), and phosphodiesterase inhibitors. Increasing evidence
shows that cAMP signaling can play a pro-apoptotic role in certain cell
type. Treatment with β-adrenergic agonists induces apoptosis in
cardiomyocytes in a cAMP/PKA-dependent manner [55–58]. Similarly,
elevating cellular cAMP concentrations by inhibiting either PDE3 or
PDE4 has been shown to promote apoptosis in cardiomyocytes [59],
mesangial cells [60] and lymphoma cells [61,62]. Aside from the direct
induction of apoptosis by pharmacological elevation of cAMP, this sec-
ondmessenger can indirectly contribute to apoptosis induced by several
death stimuli, such as TNFalpha [63], oxidative stress [64], ischemia/
reperfusion [65], gamma irradiation [66], treatment with oxysterol [67]
or amyloid beta-peptide [68]. Paradoxically, cAMP signaling also appears
to restrain the processes of apoptosis in various cell types including
neurons, gastric epithelial cells, hepatocytes, and neutrophils [69–72],
suggesting an anti-apoptotic role for the cAMP signaling pathway. Also
in prostate and breast cancer cells, the activation of β-adrenoreceptors
by epinephrine increased the resistance to apoptosis [73]. Similarly, the
activation of cAMP signaling by treatment with PGE2 or forskolin
increases cAMP levels and protects various cells against apoptosis [74,
75]. The anti-apoptotic effects of various stimuli/factors, such as adreno-
corticotropin [76], adrenomedullin [77] or glucagon-like peptide-1 [78],
have also been attributed to the cAMP/PKA signaling pathway. Finally,
in various clinical settings, high levels of cAMP in the cell have been
shown to be associated with increased resistance to apoptosis. For
instance, neutrophils from individuals with sickle cell disease exhibit
PKA-dependent resistance toward spontaneous apoptosis [79], and
increasing cAMP levels also prevents allograft rejection by modulating
apoptosis [80].
Therefore, the activation of the cAMP pathway may either promote
or suppress apoptosis. The basis of this discrepancy is not fully under-
stood and may be due to differences between cell types or models.
For instance, Iwai-Kanai et al found that treatment with the cAMP-
analogue 8-Br-cAMP markedly induced apoptosis in cardiac myocytes,
whereas it completely blocked serum depletion-induced apoptosis in
PC12 cells [57]. In addition to the differences due to cell type, compart-
mentalization of the cAMP source and/or its downstream targets within
the cell may signiﬁcantly affect the cAMP response. For example, PKA
tethered to the outer mitochondrial membrane has been shown to
phosphorylate the pro-apoptotic protein Bad, which reduces the ability
of Bad to induce apoptosis [81]. On the other hand, recent studies
suggest the presence of a cAMP/PKA signaling cascade within the
mitochondrial matrix, which is regulated by intra-mitochondrial sAC,
may play a pro-survival role via the activation of respiration and ATP
synthesis [82,83].While most studies investigating the role of cAMP signaling in cell
death suggest the involvement of PKA, recent reports also demonstrat-
ed a role for the other key downstream target, EPAC. For instance,
apoptosis induced by bile acids, Fas ligand or TNF-alpha in rat hepato-
cytes is suppressed by the cAMP/EPAC/Ras pathway, which mediates
the activation of pro-survival Akt signaling [84]. Interestingly, activation
of PKA by the speciﬁc activator 8-bromo-cAMP induces apoptosis,
whereas activation of the EPAC/Rap1 pathway by 8CPT-2 Me-cAMP
suppresses apoptosis in hematopoietic B-CLL cells (but not in other
cell types which do not express EPAC1) [85]. Therefore, cAMP may
simultaneously induce pro-apoptotic and anti-apoptotic signals through
PKA and EPAC, respectively, and the net outcome may be dependent on
the expression levels of these cAMP targets. On the other hand, several re-
ports have shown that PKA and EPAC can synergistically up-regulate the
anti-apoptotic pathways, e.g., in macrophages [86] and cardiomyocytes
[87]. Similarly to PKA, EPAC may also play a pro-apoptotic role [88]. This
controversial role for EPAC in apoptosis may be attributed to EPAC
compartmentalization, which is achieved by the membrane-targeting
disheveled/Egl-10/pleckstrin domain [27,89] and the Ras-association
domain [90].
cAMP signaling has also been shown to regulate the other form of
programmed cell death, autophagy. The classic autophagy pathway in
mammalian cells involves mammalian target of rapamycin (mTOR).
Recent studies have also shown an mTOR-independent activation of
autophagy in adipocyte-derived mesenchymal stem cells through
the activation of the PKA/ERK axis [91]. In contrast, the cAMP/EPAC
signaling may inhibit autophagy by activation a series of complex
signaling components involving the cAMP-Epac-Rap2B-PLC-ε-IP3 and
Ca2+-calpain-Gsα pathways [92,93].
Apart from programmed cell death, cAMP signaling may also
contribute to accidental necrotic cell death. Ischemia/reperfusion is a
frequently used model for investigating necrotic cell death. Several
reports demonstrated protective effects of cAMP-signaling against ne-
crosis in brain, liver and heart [94–99]. The beneﬁcial effectsweremain-
ly attributed to PKA-dependent phosphorylation/activation of several
distinct targets, e.g., heat shock proteins, Akt, p38-MAP kinases, and
eNOS [100–103].
In conclusion, the cAMP signaling pathway plays an essential role in
programmed cell death by either promoting or inhibiting it. The net
outcome ultimately depends on the treatment model and cell type, as
well as the expression and compartmentalization of cAMP effectors.
Furthermore, the involvement of different cAMP pools, i.e., sub-
plasmalemmal cAMP produced by tmAC or intracellular (cytosolic,
nuclear or mitochondrial) cAMP produced by sAC, may also contribute
to the net effect, i.e., death or survival.
4. sAC and cell death
Initial studies investigating the intracellular distribution of sAC re-
vealed co-localization of this cyclase with mitochondria [11]. Because
mitochondria play a fundamental role in apoptosis [104], we hypothe-
sized that sAC may modulate the mitochondrial apoptosis pathway.
Applying two models to simulate common clinical situations leading
to apoptosis, i.e., ischemia and acidosis [105–107] in rat coronary endo-
thelial cells [108] and in rat cardiomyocytes [65], we found that sAC is a
key enzyme that controls the stress-induced activation of themitochon-
drial apoptosis pathway (Table 1). Further analyses of the downstream
signaling revealed a key role for PKA in sAC signaling. In a recent study
[67], we also found that the sAC/PKA axis is involved in the activation of
the mitochondrial apoptosis pathway in oxysterol-treated smooth
muscle cells. While we detected an increase in intracellular cAMP
concentrations under acidic stress in endothelial cells [108], we were
unable to detect a rise in total cAMP or in the sAC-speciﬁc cAMP pool
in ischemic cardiomyocytes or in oxysterol-treated smooth muscle
cells [65,67]. Interestingly, in ischemic cardiomyocytes, sAC-generated
cAMP appeared to be reduced rather than increased (unpublished
Table 1
Role of sAC in apoptosis.
Cells Apoptosis induction Role of sAC Apoptotic pathway Downstream signaling Reference
Corneal endothelial cells Staurosporine Anti-apoptotic Mitochondrial PKA [125]
Coronary endothelial cells Ischemia acidosis Pro-apoptotic Mitochondrial PKA/Bax [108]
Cardiomyocytes Ischemia /reperfusion Pro-apoptotic Mitochondrial PKA/Bax [65]
Aortic smooth muscle cells Oxysterols Pro-apoptotic Mitochondrial PKA/Bax [67]
Aortic smooth muscle cells ROS Pro-apoptotic Mitochondrial PKA/PP1/p38/Bad [64]
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anoxia. Furthermore, in ischemic/acidic medium, the bicarbonate
concentration was reduced tenfold in order to maintain pH 6.4 at 5%
CO2. Therefore, it seems unlikely that bicarbonate mediates sAC activa-
tion in our studies. Aside from bicarbonate, Ca2+ has been shown to
activate sAC in mammalian cells [10,15]. Incubating endothelial cells
or cardiomyocytes under simulated ischemia leads to Ca2+ overload
[109–111], which may contribute to the activation of sAC (at least in
endothelial cells). In contrast, direct measurements of cytosolic Ca2+
concentrations in smooth muscle cells did not reveal Ca2+ changes
under oxysterol treatment [67]. Therefore, besides acidosis-induced
activation of sAC in endothelial cells [108], other models of apoptosis
[64,65,67] seem to exclude stimulation of sAC activity as a possible
mechanism triggering apoptosis. Nevertheless, it is important to re-
member that only the whole cell cAMP content has been analyzed in
these studies. Because Ca2+ concentration may be different between
various compartments, e.g., between cytosol and mitochondria, the
activity of sAC and consequently the cAMP content may also vary be-
tween compartments. Further cAMP analyses within the mitochondria
or nuclei should reveal whether pro-apoptotic stimuli may differently
alter the activity of sAC in these compartments.
Altogether these data suggest that mechanisms other than simple
stimulation of sAC activity likely mediate sAC-dependent control of
mitochondrial apoptosis. Indeed, an analysis of its intracellular distribu-
tion, revealed that sAC translocates from the cytosol to the mitochondria
in each of these studies [65,67,108]. Furthermore, the translocation of sAC
was always accompanied by mitochondrial translocation of the pro-
apoptotic protein Bax. Bax translocation seems to be a key downstream
event in sAC-dependent apoptosis: (i) treatment with a Bax-inhibiting
peptide prevented apoptosis [65]; (ii) inhibiting sAC or PKA abrogated
themitochondrial Bax translocation [65,67]; and (iii) PKAphosphorylates
Bax at Thr167 [65,67], which is known to promote mitochondrial Bax
binding [112]. Therefore,mitochondrial sAC-translocation, rather than ac-
tivation, is the key mechanism responsible for triggering sAC-dependent
apoptosis. This conclusion is in agreement with the generally accepted
model of PKA signaling, which emphasizes the role of PKA-anchoring
proteins in tethering and localizing PKA pools to discrete subcellular
microdomains near kinase-speciﬁc downstream substrates [113,114]. In
particular, the compartmentalization of PKAwithinmitochondrial micro-
domains [115,116] and the contribution of PKA tomitochondrial apopto-
sis [117,118] have both been demonstrated. Therefore, the stress-induced
translocation of sAC from the cytosol to themitochondriamay lead to the
selective activation of PKA localized within mitochondrial microdomains
followed by the phosphorylation and activation of a sub-mitochondrial
Bax pool and the release of cytochrome c. The precise mechanisms
promoting mitochondrial translocation of sAC in response to different
stress stimuli remains under investigation.
An important feature of sAC-dependent apoptosis is the generation
of reactive oxygen species (ROS). Evidence has accumulated demon-
strating the involvement of PKA in ROS production induced by various
stresses [119,120]. ROS have also been found to signiﬁcantly contribute
to oxysterol- [121,122] or ischemia/reperfusion-induced [123] apopto-
sis. Consistent with these reports, we observed marked sAC- and PKA-
dependent ROS production in our cell death models [65,67]. Inhibition
of complexes I (rotenone) or II (TTFA) of the mitochondrial respiratorychain blocked ROS formation, suggesting that mitochondria are the
main source of the ROS. Therefore, these ﬁndings indicate that ROS
form a direct causal link between sAC and mitochondrial apoptosis. In
contrast to our ﬁndings, reports from Acin-Perez et al. [82,83] suggest
that intra-mitochondrial sAC/PKA signaling limits mitochondrial ROS
production and that inhibiting sAC or PKA leads to a slight but signiﬁ-
cant increase in ROS production. This discrepancy may be due to differ-
ences between the models, i.e., physiological conditions in Acin-Perez's
studies compared with apoptosis induction in our studies. Indeed,
modulating sAC/PKA activity only altered ROS production by 30–40%
in the studies from Acin-Perez [82,83], which is in the range for the
regulation of the mitochondrial biogenesis of ROS as a second messen-
ger [124]. In contrast, ROS production increased by several fold in our
studies. Furthermore, we found that the extracellular pool rather than
intra-mitochondrial pool of sAC is involved in ROS generation [67].
Ourmost recent study in smoothmuscle cells seemed to identify yet
another sAC-dependent apoptosis pathway induced by oxidative stress,
i.e., by treatment with H2O2 or DMNQ [64]. We observed similar initial
steps of the sAC-dependent apoptosis pathway, i.e., mitochondrial sAC
translocation and the involvement of PKA; however, we did not detect
Bax translocation suggesting that a different downstream signaling
cascade was involved. In particular, the sAC/PKA-dependent activation
of protein phosphatase-1 leads to the dephosphorylation of p38. The
loss of p38 activity attenuates the phosphorylation/inactivation of pro-
apoptotic Bad, which promotes the activation of the mitochondrial
pathway of apoptosis. This difference in sAC-dependent apoptosis
pathway may be due to differences in pro-apoptotic stress factors.
Indeed, in a simulated ischemia model, acidosis or oxysterol treatment-
induced sAC translocation seems to be an initial event, followed by
Bax-dependentmitochondrial injury, which in turn leads to ROS forma-
tion. In contrast, in thismost recent study [64], ROSwere applied direct-
ly to cells, i.e., ROS were upstream of sAC. In summary, these studies
demonstrate the key role of sAC in promoting the mitochondrial
apoptosis pathway independent of the cell type and stress factor.
In contrast to our ﬁndings, Li et al. [125] identiﬁed a protective role
for sAC against staurosporine-induced apoptosis in bovine corneal
endothelial cells (Table 1). The authors found that incubating cells in
bicarbonate-rich medium (40 mmol/l) suppressed staurosporine-
induced apoptosis in a sAC-dependent manner. The discrepancy
between this study and ours may be ascribed to differences in the
models used. First, our models applied acute treatment with simulated
ischemia, acidosis or ROS (3-6 hrs), while Li et al were studying long-
term treatment with staurosporine (17 hrs). Second, Li et al reported
an increase in sAC activity and cellular cAMP content after 48 hrs
incubation in bicarbonate-rich medium. This may markedly affect pro-
survival signaling pathways. Indeed, our recent report [126] demon-
strated that enhancement of the sAC/EPAC/Rap1/B-Raf axis promotes
tumor cell proliferation. Because B-Raf and the downstream ERK1/2
kinase play a pro-survival role in various cell types, it is possible that
the long-term activation of sAC by bicarbonate may precondition cells
and lead to a protective effect against apoptosis. Another recent study
by Corredor et al. [127], investigating the survival of postnatal rat retinal
ganglion cells, demonstrated the importance of sAC activity in basal and
electrical stimulation-induced cell survival. Although it is unclearwhich
type of cell death was observed in this study, the authors found that the
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of sAC in axon growth. Again, this study included long-term treatments
(24–48 hrs) with bicarbonate, suggesting the activation of sAC-
dependent pro-survival pathways, i.e., EPAC/B-Raf [126] or PKA-
dependent ATP-synthesis [82,83].
Aside from apoptosis, sAC may also play a role in necrotic cell death.
This is particularly relevant for the necrotic death of cardiomyocytes
during reperfusion. Acute reperfusion is known to require the rapid re-
covery of ATP synthesis in order to both extrude the excessive cytosolic
Ca2+ accumulated during ischemia and avoid reperfusion-induced
hypercontracture and necrotic cell death [128,129]. Because sAC has
been shown to support mitochondrial ATP synthesis due to PKA-
dependent phosphorylation of certain key proteins in the respiratory
chain [83], sAC may play a protective role against reperfusion-induced
injury in cardiomyocytes. Indeed, pilot experiments in our laboratory
using cultured adult rat cardiomyocytes, demonstrating that sAC
inhibition in reperfused cardiomyocytes blocked the recovery of
mitochondrial function and cytosolic Ca2+ homeostasis and leads to
cell death, support this hypothesis (Y. Abdallah and Y. Ladilov, unpub-
lished observations).
In conclusion, sAC seems to play a dual role in cell death, which is
dependent on the localization of sAC (Fig. 1). Studies from our group
suggest that the cytosolic pool of sAC promotesmitochondrial apoptosis
by triggering mitochondrial Bax binding in a PKA-dependent manner.
Alternatively, recent studies from other groups suggest that sAC is local-
ized within themitochondria and controls the phosphorylation/activity
of certain proteins in the respiratory chain, thereby playing a pro-
survival role. Activating the mitochondrial sAC/PKA pathway promotes
ATP synthesis and attenuates the production of oxygen radicals [82,83].
sAC has been found to be the only source for cAMP in mitochondria
[130]. Therefore, as a bicarbonate and Ca2+ sensor, mitochondrial sACFig. 1.Mechanisms for the sAC-dependent regulation of cell death and growth. (1) Various st
subsequent activation of PKA localized proximal to the outer mitochondrial membrane leads t
mitochondria, which activates the mitochondrial pathway of apoptosis. (2) Conversely, the intra
of several proteins in the mitochondrial electron transport chain (ETC), which leads to increased
and survival through the activation of the EPAC/B-Raf pathway. (4) The presence of a nuclear sACmay couple the activity of the tricarboxylic acid cycle (the main source
of cellular CO2 production), along with alterations in the intramito-
chondrial Ca2+ concentration [130], to oxidative phosphorylation activ-
ity and the rate of ATP synthesis.
5. Role of cAMP signaling in cell growth
The term “cell growth” is used in the context of either (i) cell devel-
opment or (ii) cell division/proliferation. In the ﬁrst case, cells increase
their cytoplasmic or organelle volume during the G1-phase of the cell
cycle or increase their genetic material via replication in S-phase. In
contrast, cell division refers to the growth of a cell population due to
the division of “mother cells” to produce "daughter cells" (M-phase).
cAMP signaling, together with other signaling pathways, plays a funda-
mental role in cell growth. However, the data on this topic remain
controversial. Various studies report that activation of cAMP signaling
may promote [131,132] or suppress [133,134] proliferation. The basis
for this discrepancy is unclear and may be due to differences in cell
types and experimental models. For example, cAMP stimulates the
proliferation of epithelial cells, hepatocytes, adipocytes, and pancreatic
β-cells, whereas it inhibits the proliferation of ﬁbroblasts, smooth
muscle cells, neoplastic B-cells, and malignant glioma cells [135,136].
The cell-type-speciﬁc spatial restriction or compartmentalization of
the cAMP source and its downstream targets PKA and EPAC within the
cell may also signiﬁcantly affect the net cAMP response. In particular,
spatially discrete subpopulations of PKA generated by PKA-anchoring
proteins may have opposite effects on proliferation due to C-Raf-
dependent inhibition or B-Raf-dependent stimulation of the Raf/MEK/
ERK signaling pathway [137]. Similarly, a spatial cAMP gradient can be
formed through the targeted degradation of cAMP by phosphodiester-
ases, leading to a selective increase in the cAMP concentration in closeress factors lead to the translocation of the cytosolic pool of sAC to the mitochondria. The
o the phosphorylation of the pro-apoptotic protein Bax followed by the binding of Bax to
-mitochondrial sAC/PKA pathway promotes cell survival via the phosphorylation/activation
mitochondrial ATP synthesis. (3) Outside the mitochondria, sAC promotes cells proliferation
/PKA/CREB pathway may contribute further to cell survival and growth.
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are additionally complicated by the activation of the other key cAMP
target, EPAC. As with PKA, EPAC has both positive and negative effects
on cell growth. The stimulatory effect of EPAC on proliferation has
been suggested to involve the activation of B-Raf signaling by the
small GTPase Rap1, which is a direct effector of EPAC [138]. Moreover,
recent studies revealed a functional role for EPAC/Rap1 signaling in
promoting the G2/M transition. Qiao et al. [139] found dramatic alter-
ations in the spatial distribution of EPAC during the cell cycle: EPAC
exhibits a predominantly perinuclear localization during interphase,
whereas EPAC dissociates from the nuclear envelope during prophase/
prometaphase and associates with the mitotic spindle and the centro-
somes in metaphase. In line with these ﬁndings, a recent report
suggested that MEK1, which is a downstream target of Rap1/B-Raf sig-
naling, plays an essential role in spindle organization and chromosomal
stability during mitosis [140]. The disruption of this signaling pathway
impairs spindle formation [141] and leads to the down-regulation of
cyclin B1 [142], a key protein involved in the G2/M transition, as well
as cell cycle arrest in G2 phase [143]. In addition to the MAP kinase
pathway, recent studies suggest that the pro-proliferative effects of
EPACmay be related to theAkt-dependent activation of themammalian
target of rapamycin (mTOR) [131,144].The mechanisms underlying the
anti-proliferative effects of EPAC are not completely understood and
may include increases in the levels of cell cycle inhibitor proteins such
as p21 and p27 [145,146].
EPAC and PKA are ubiquitously expressed in all tissues and have a
similar afﬁnity for cAMP [42]. Increases in intracellular cAMP levels
may lead to the simultaneous activation of both PKA and EPAC in the
same or in different compartments. The question therefore arises
whether the effect of cAMP on cell growth is due to the activation of
EPAC, PKA, or both. Increasing evidence suggest that PKA and EPAC
can exert opposing effects due to the differential regulation of key
signaling pathways involved in proliferation, including Akt [147] and
ERK1/2 [148]. On the other hand, several reports have also shown that
EPAC and PKA can exert synergistic effects on downstream signaling
to promote or inhibit proliferation [86,132,134].
Another form of cell growth involves an increase in cell size between
two division cycles. Eukaryotic cells commit to cell division only if they
have reached a critical size and a critical rate of protein synthesis.
Among several cell signaling pathways, cAMP signaling has been
shown to control this form of cell growth [149,150]. The role of cAMP
signaling in non-proliferative cell growth is evolutionary conserved
and can be observed in yeast [149,150] as well as in mammals [151].
Aside from controlling physiological increases in cell size, numerous
reports conﬁrm a key role for cAMP signaling in pathological cell size
increases. Hypertrophy represents the most well-studied form of non-
mitotic cell growth; it is related to themost widely distributed patholo-
gy in modern society—cardiac hypertrophy. Intensive research over the
last few decades has revealed numerous signaling pathways regulating
cardiac hypertrophy [151]. cAMP signaling may play a role in this
pathology, both indirectly, through the modulation of other pathways
such as MAP kinase and Akt [147,148], and directly, mediating the
effects of chronic β-adrenergic stimulation [152]. Transgenic over-
expression studies indicate the importance of cAMP signaling in the in-
duction of hypertrophy in vivo [153,154]. Other studies have conﬁrmed
the key role of PKA and EPAC in the β-adrenergic signaling-induced
myocardial hypertrophy [155,156]. The pro-hypertrophic effects of
EPAC involve small GTPases Rap2B, Rac and H-Rac, as well as phospho-
lipase C, the Ca2 + -sensitive phosphatase calcineurin and its primary
downstream effector, NFAT [156–158]. Furthermore, EPAC activation
leads to the nuclear export of HDAC4 and HDAC5, followed by the acti-
vation of the transcription factor MAF2 [157]. In contrast to EPAC, the
role of PKA in cardiac hypertrophy remains controversial. PKA may
phosphorylate HDAC5 and prevent its nuclear export, leading to the in-
hibition of cardiomyocyte hypertrophy in vitro [159]. Conversely,
in vitro and in vivo studies argue for a pro-hypertrophic role of PKA[155,160,161]. The underlying cellular mechanism of PKA-dependent
hypertrophic response in the heart is complex, and the importance of
AKAP has been emphasized. Particularly, AKAP may recruit PKA to the
outer nuclear membrane into a multi-enzyme signaling complex con-
taining PDEs, protein phosphatase 2A, ryanodine receptor 2, calcineurin,
NFAT, EPAC, and ERK5 to integrate the elevation of cAMP in hypertro-
phic signaling [162]. On the other hand, recent studies suggest that
the catalytic subunit of PKA, upon stimulation in the cytosol, may trans-
locate to the nucleus and promote hypertrophic responses independent
of AKAP [160]. Furthermore, the presence of functional sAC/PKA/CREB
signaling in the nucleus [163] suggests a role for a nuclear pool of PKA
in CREB-mediated hypertrophy.
In conclusion, the effect of cAMP signaling on cell growth is complex
and controversial. The discrepancies may be due to differences in the
cell type, the speciﬁc cellular context, and themode of cAMPmanipula-
tion. The effects are also strongly dependent on the spatiotemporal
distribution of the key cAMP effectors PKA and EPAC. Furthermore,
the cross-talk between cAMP signaling and other pathways (MAPK,
Akt) plays an essential role in the overall effect on cell growth.
Finally, one should note that the majority of studies examining
cAMP signaling were focused on the sub-plasmalemmal pool of
cAMP generated by tmAC activation, whereas the role of intracellular
cAMP was largely ignored. Recent reports demonstrate that cell
growth is also affected by this intracellular pool of cAMP produced
by sAC.
6. sAC and cell growth
The ﬁrst indications of a role for sAC in cell growthwere provided by
studies from Zippin et al. [163,164]. First, the existence of a bicarbonate-
sensitive nuclear cAMP signaling microdomain that mediates the PKA-
dependent activation of the transcription factor CREB was revealed.
This nuclear cAMP signaling pathway has been found to function inde-
pendently from canonical tmAC signaling. Using a model of epithelial
differentiation, Zippin et al. [164] then found that sAC migrates into
the nucleus when differentiated cells are induced to re-enter the cell
cycle. The authors also observed predominantly nuclear sAC localization
in keratinocytes from certain hyperproliferative skin diseases. Although
these reports do not directly show a causal role for sAC, they neverthe-
less support that sAC may be involved in cell proliferation. In a recent
study,we found that sAC is overexpressed in human prostate carcinoma
comparedwith benign prostatic tissue [126] (Table 2). Similar sAC over-
expressionwas found in the human prostate carcinoma cell lines LNCaP
and PC3when comparedwith the normal human prostate epithelial cell
line PNT2. Suppressing the sAC activity of LNCaP and PC3 cells through
sAC inhibitor treatment or sAC knockdown signiﬁcantly reduced the
rate of proliferation, led to lactate dehydrogenase release, and induced
apoptosis. Subsequent analysis of the underlying cellular mechanisms
revealed that the inhibition of sAC leads to cell cycle arrest in G2
phase. This effect results from the sAC inhibition-induced down-
regulation of cyclin B1 and CDK1, which are the key proteins involved
in the G2/M transition. Moreover, the sAC-dependent regulation of
proliferation involves the EPAC/Rap1/B-Raf signaling pathway, whereas
protein kinase A does not play a role.
EPAC has also been shown to play an important role in controlling
proliferation in different cell types, including prostate carcinoma cells
[131,135,144]. A recent study by Misra and Pizzo [131] demonstrated
that treatment with an EPAC-speciﬁc cAMP analog promotes prolifera-
tion in prostate carcinoma cells in a PKA-independent manner. In our
study, EPAC activity was strongly dependent on sAC activity, as inhibi-
tion of sAC signiﬁcantly reduced the amount of GTP-bound Rap1
[126]. Thus, the overexpression of sAC in cancer cells seems to lead to
the overactivation of EPAC/Rap1/B-Raf axis. As discussed above
(Section 5: Role of cAMP signaling in cell growth), this particular path-
way plays a fundamental role in promoting the G2/M transition
[139–141]. Therefore, these data suggest a role for sAC in promoting
Table 2
Role of sAC in cell growth.
Cells Treatment Role of sAC Downstream signaling Reference
Rat embryonic neurons Netrin-1 Promoting axonal growth PKA [167]
Rat postnatal retinal ganglion cell Electrical stimulation, bicarbonate Promoting axonal growth PKA [127]
Cardiomyocytes β1-stimulation Pro-hypertrophic Unknown [169]
LNCaP/PC3 Inhibition /knockdown of sAC Pro-proliferative EPAC/B-Raf/ ERK1/2 [126]
PNT2 Overexpression of sAC Pro-proliferative B-Raf [166]
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signaling. Interestingly, a recent study by Onodera et al. [165] using a
3D culture of breast cancer cells demonstrated that sAC is co-localized
with pyruvate kinase M2. The authors suggest that the production of
ATP by pyruvate kinase is directly linked to the sAC-mediated conver-
sion of ATP to cAMP. This sAC-mediated cAMP production leads to
malignant phenotypes in epithelial cells via the EPAC/Rap1 pathway.
Thus, these data, together with our investigation [126], demonstrate
the importance of sAC in oncogenesis.
In a recent follow-up study [166], we found that transfecting normal
prostate epithelial PNT2 cells with a cDNA encoding an active form of
sAC signiﬁcantly increases the cellular cAMP content and the prolifera-
tion rate. The transfected cells display signiﬁcantly greater resistance to
ionizing radiation, in other words, irradiation-induced cell death and
suppression of proliferation were both attenuated by sAC expression.
Correspondingly, the suppression of sAC activity in tumor LNCaP
cells, which show high sAC expression rate, augmented the anti-
proliferative and cytotoxic effects of irradiation. Therefore, this study
indicates a possible application for sAC as a target in radiotherapy, at
least for some forms of cancer.
Aside from cell proliferation, sAC also seems to play a role in non-
proliferative cell growth (Table 2). An initial study by Wu et al. [167]
demonstrated that sAC is expressed in embryonic neurons and gener-
ates cAMP in response to netrin-1. Moreover, the overexpression of
sAC promotes axonal outgrowth, whereas sAC inhibition interferes
with the effects of netrin-1. In agreementwith this study, a recent report
from Corredor et al. [127] demonstrated that stimulating sAC with
bicarbonate increases axon growth in cultured retinal ganglion cells,
whereas suppressing sAC attenuates axon growth. However, an inde-
pendent study by Moore et al. [168] could not conﬁrm the role of sAC
in netrin-induced axon outgrowth. The origin of this discrepancy is un-
clear andmay be due to differences in treatment and culture conditions
of the embryonic neurons. In particular, high levels of sAC expression
were observed in rat embryonic neurons from the dorsal root ganglia
and dorsal spinal cord as well as in rat postnatal retinal ganglion cells
[127,167], but only low levels of sAC expression could be found in
embryonic dorsal root ganglia and spinal commissural neurons in the
model used in the Moore et al. study [168].
Our group also investigated the role of sAC in non-proliferative cell
growth using primary culture of adult rat ventricular cardiomyocytes
[169]. Given that these cells are terminally differentiated, only hypertro-
phic growth can be induced. By applying chronic β1-adrenergic stimu-
lation (24 hrs) to induce cardiomyocyte hypertrophy, we found that
sAC plays a key role in this process. Indeed, suppressing sAC with the
speciﬁc inhibitor KH7 or via sAC-knockdown abolished the hypertro-
phic effects of β1-adrenergic stimulation.
Together, the current data suggest that sAC plays an essential role
in regulating both proliferative and non-proliferative cell growth.
Although the downstream pathways involved in the sAC-dependent
control of non-proliferative cell growth have yet to be elucidated, the
role of the EPAC/Rap1/B-Raf axis has thus far been demonstrated for
the sAC-dependent proliferation of prostate tumor cells [126,166].
Interestingly, Stessin et al. [170] also demonstrated activation of sAC-
Rap1 pathway after treatment with nerve growth factor in PC12 cells.
Since this growth factor leads to differentiation of these cells, one maysuppose that in somemodels sAC/Rap1 pathwaymay lead to differenti-
ation rather than to proliferation.
7. Conclusions and perspectives
The proper regulation of cell death and growth plays a fundamental
role in the existence of living beings and consists of multiple evolution-
arily conserved and newly developed mechanisms. cAMP signaling
makes an essential contribution to the control of these cellular func-
tions. This system is complex and has a well-organized spatiotemporal
structure. The discovery of sAC as an alternative, intracellular source of
cAMP has signiﬁcantly extended our knowledge of the spatial distribu-
tion of cAMP signaling. Furthermore, this discovery resolves several
questions regarding the cAMP-dependent regulation of intracellular tar-
gets, e.g., those in the nucleus or mitochondria. Although the study of
sAC's role in cell death and growth is still a developing research area,
recent reports clearly demonstrate the following sAC-dependentmech-
anisms (Fig. 1): (i) A cytosolic pool of sAC controls the mitochondrial
apoptosis pathway via the PKA/Bax-pathway. (ii) Intra-mitochondrial
sAC controls mitochondrial respiration and bioenergetics in a PKA-
dependent manner. (iii) sAC promotes cell proliferation and devel-
opment in an EPAC- and PKA-dependent manner. These initial studies
provide the basis for the development of new strategies for the treat-
ment of diseases arising from the dysregulation of cell growth, such as
cancer and cardiac hypertrophy, or from enhanced cell death, including
neurodegenerative and ischemic diseases.
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